INVA(Innoviva, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $391.87M | $331.34M | $310.46M | $358.71M | $411.33M |
| 毛利润 | — | — | $246.04M | $296.21M | $307.67M |
| 营业利润 | $375.10M | — | $113.89M | $166.87M | $163.75M |
| 净利润 | $368.84M | $220.26M | $179.72M | $23.39M | $271.17M |
| 经营现金流 | $363.81M | $201.73M | $141.06M | $188.69M | $196.93M |
| 自由现金流 | $363.81M | $201.66M | $140.65M | $188.42M | $195.80M |
| 摊薄每股收益 | $2.87 | $2.37 | $2.20 | $0.36 | $3.30 |